
ImageneBio, Inc. (NASDAQ:IMA – Free Report) – Equities research analysts at HC Wainwright issued their FY2026 earnings per share (EPS) estimates for shares of ImageneBio in a research note issued to investors on Friday, November 13th. HC Wainwright analyst A. He expects that the company will earn ($3.55) per share for the year. HC Wainwright currently has a “Strong-Buy” rating on the stock. The consensus estimate for ImageneBio’s current full-year earnings is ($3.46) per share. HC Wainwright also issued estimates for ImageneBio’s Q4 2026 earnings at ($1.07) EPS, Q1 2027 earnings at ($1.19) EPS, Q2 2027 earnings at ($1.34) EPS, Q3 2027 earnings at ($1.51) EPS, Q4 2027 earnings at ($1.69) EPS, FY2027 earnings at ($5.73) EPS, FY2028 earnings at ($5.35) EPS, FY2029 earnings at ($5.03) EPS and FY2030 earnings at ($4.95) EPS.
Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of ImageneBio in a research report on Friday, September 25th. One investment analyst has rated the stock with a Strong Buy rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $28.00.
ImageneBio Stock Performance
Shares of IMA opened at $3.81 on Tuesday. The company’s fifty day moving average is $4.31 and its 200 day moving average is $5.43. ImageneBio has a fifty-two week low of $3.00 and a fifty-two week high of $7.89. The stock has a market capitalization of $47.47 million, a PE ratio of -0.83 and a beta of 0.83.
ImageneBio (NASDAQ:IMA – Get Free Report) last posted its earnings results on Monday, November 9th. The company reported ($0.91) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.83) by ($0.08).
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Blue Owl Capital Holdings LP boosted its stake in shares of ImageneBio by 23.7% during the 3rd quarter. Blue Owl Capital Holdings LP now owns 1,135,081 shares of the company’s stock worth $5,199,000 after purchasing an additional 217,389 shares during the period. Stonepine Capital Management LLC bought a new position in ImageneBio during the 2nd quarter valued at about $539,044,000. Trails Edge Capital Partners LP bought a new position in ImageneBio during the 2nd quarter valued at about $1,663,824. Hsbc Holdings PLC bought a new position in ImageneBio during the 2nd quarter valued at about $208,000. Finally, Cable Car Capital LP purchased a new stake in ImageneBio in the 2nd quarter worth about $4,611,000. Hedge funds and other institutional investors own 75.00% of the company’s stock.
Recent ImageneBio Headlines
These are some of the IMA headlines that stood out recently:
- Positive Sentiment: A report says ImageneBio’s third-quarter loss narrowed as clinical trials advanced, which may support investor confidence in its development progress. ImageneBio stock: Q3 loss narrows as clinical trials advance
- Positive Sentiment: HC Wainwright maintained a “Strong-Buy” rating on IMA, offering a favorable analyst signal. ImageneBio analyst estimates
- Negative Sentiment: HC Wainwright expects continued losses, estimating a $3.55-per-share loss for FY2026 and $5.73 for FY2027, with losses also projected through FY2030. These forecasts underscore the company’s ongoing funding and execution risks. ImageneBio analyst estimates
About ImageneBio
ImageneBio, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for immune-mediated and inflammatory diseases. Its research and development pipeline includes investigational medicines at various stages of clinical development; the company does not yet have marketed products. Key programs include IMG-007, an investigational antibody targeting OX40 being studied for atopic dermatitis and other inflammatory conditions, and IMG-004, an oral investigational BTK inhibitor for immune-mediated diseases.
Recommended Stories
- Five stocks we like better than ImageneBio
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Receive News & Ratings for ImageneBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImageneBio and related companies with MarketBeat.com's FREE daily email newsletter.
